Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc B Garnick

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|May 16, 2019
More on Long-Term Effects of Finasteride on Prostate Cancer MortalityMarc B Garnick
JAMA|April 5, 2012
Recommendations on use of prostate-specific antigen for prostate cancer screeningMarc B Garnick
Harvard Health Letter|March 10, 2012
Ask the doctor. I take Avodart for my enlarged prostate. But I heard that Avodart increases prostate cancer risk. Is that true? Should I quit taking Avodart?Marc B Garnick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Reply to S. Barni et Al and M. Sun et AlMarc B Garnick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Redefining the refined retroperitoneal lymph node dissection in testis cancer: a SWOT analysis of nonrandomized dataMarc B Garnick
Urology|June 2, 2010
Editorial commentMarc B Garnick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case studyMarc B Garnick
Scientific American|February 3, 2012
The great prostate cancer debateMarc B Garnick
BJU International|February 29, 2012
Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancerMarc B Garnick
Oncology (Williston Park, N.Y.)|July 25, 2009
Important considerations in LHRH antagonist therapy for prostate cancerMarc B Garnick
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|May 16, 2019
More on Long-Term Effects of Finasteride on Prostate Cancer MortalityMarc B Garnick
JAMA|April 5, 2012
Recommendations on use of prostate-specific antigen for prostate cancer screeningMarc B Garnick
Harvard Health Letter|March 10, 2012
Ask the doctor. I take Avodart for my enlarged prostate. But I heard that Avodart increases prostate cancer risk. Is that true? Should I quit taking Avodart?Marc B Garnick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Reply to S. Barni et Al and M. Sun et AlMarc B Garnick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Redefining the refined retroperitoneal lymph node dissection in testis cancer: a SWOT analysis of nonrandomized dataMarc B Garnick
Urology|June 2, 2010
Editorial commentMarc B Garnick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case studyMarc B Garnick
Scientific American|February 3, 2012
The great prostate cancer debateMarc B Garnick
BJU International|February 29, 2012
Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancerMarc B Garnick
Oncology (Williston Park, N.Y.)|July 25, 2009
Important considerations in LHRH antagonist therapy for prostate cancerMarc B Garnick
Pageof 5